Clinical trial registry record

Effects of an Omega-3 Fatty Acid-based Supplement on Healthy Ageing

A registered study indexed because it matched monitored longevity research terms. Registry status: Unknown. Registration does not establish safety or effectiveness.

Plain-language guide

Five questions to ask about this record

What this is
A clinical study registration, not a result or recommendation.
Why it may matter
The registry currently reports Unknown.
Evidence
Registered phase not reported study.
Main limitation
Registration does not prove that the intervention works, is safe, or is available to you.
What changed
Registry metadata was last updated January 14, 2025.
Where to verify
Open the primary registry below for eligibility, locations, contacts, and current status.
Registry ID
NCT06150261
Last registry update
January 14, 2025
Status
Unknown
Phase
Phase not reported
Sponsor
Helse Stavanger HF
Enrollment
100
Countries
Norway
Match confidence
100%
Source feed
ClinicalTrials.gov
Automated source synopsis

A registered study indexed because it matched monitored longevity research terms. Registry status: Unknown. Registration does not establish safety or effectiveness.

Evidence snapshot

What the source actually supports

Evidence stage
Phase not reported
Study design
RANDOMIZED · PARALLEL · PREVENTION · DOUBLE
Evidence population
Human clinical study registration
Participants
100
Population
ALL · 55 Years to 100 Years
Duration
2023-12-08 to 2025-12-31
Intervention
AvailOm; Placebo
Comparator
Placebo
Outcomes measured
Effects of Availom on DNA methylation — 6 months; Effects of Availom on inflammation — 6 months; Effects of Availom on plasma lipids — 6 months; Effects of Availom on in vitro neurogenesis markers — 6 months; Effects of Availom on brain-derived neurotrophic factor — 6 months; Effect of Availom on microbiome changes — 6 months; Investigate potential moderators of the effect of Availom on microbial composition — 6 months; Effects of Availom on cognition as measured by use of MoCA — 6 months; Effects of Availom on cognition as measured by use of CERAD — 6 months; Effects of Availom on muscle function as asessed by TUG — 6 months; Effects of Availom on muscle function as assessed by grip strength — 6 months; Effects of genotype on association between Availom and genotype — 6 months
Reported result
No reusable finding-level result is available in this record.

Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.

Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.

Source supportStructured registry protocol metadata; no finding-level conclusion is generated.

Trial stage · Phase not reportedA trial phase describes development stage; it does not establish a positive result.
Phase 1Phase 2Phase 3Phase 4

Registration and recruitment status do not establish safety, efficacy, or regulatory approval.

Why this record appears here · 100% topic match

The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.

  • Omega-3 fatty acids · 100%Title contains controlled topic terminology. Summary contains controlled topic terminology. Title supplies ageing or longevity context.

Automated source check 100% · update recency 65%. These figures help sort records; they are not medical ratings.

omega 3 fatty acids
Read the original source →Export JSON